RECOMBINANT DNA CONTAINING A HERPES SIMPLEX VIRUS GENE OR A FRAGMENT THEREOF, YEAST TRANSFORMED WITH SAID RECOMBINANT DNA, AND METHOD FOR THE PRODUCTION OF HERPES SIMPLEX VIRUS PROTEINS

Abstract: Novel recombinant plasmid obtained by inserting a herpes simplex virus gene (e.g. HSVgB), optionally a frag­ ment of the gB gene without the 3′-region, into a shuttle vector containing both yeast gene and E. coli gene and carrying the expression control region of the repressible acid phosphatase gene of yeast; novel transformed yeast obtained by transforming yeast with said recombinant plasmid and method for the production of herpes simplex virus proteins (e.g. gB, and chemiric proteins) in a high yield and with high purity by culturing said transformed yeast. The herpes simplex virus proteins are useful for the preparation of HSV vaccines and diagnostic reagents for herpes simplex infections.

Description: The present invention relates to a novel recombinant DNA containing a herpes simplex virus gB gene or a fragment thereof, a yeast transformed with said recombinant DNA, and a method for the production of herpes simplex virus gB proteins, wherein a genetic engineering technique is applied to the production of the desired herpes simplex virus proteins which have a high purity and are useful for the production of herpes simplex vaccine effective for the prophylaxis of herpes simplex virus infections. More particularly, the present invention provides a novel recombinant DNA which is obtained by inserting a or a fragment thereof HSVgB gene, or a fragment thereof into a shuttle vector which can replicate in both Escherichia coli and yeast downstream of the expression control region of the repressible acid phosphatase gene (said region being hereinafter referred to as "acid phosphatase promoter" or "acid phosphatase gene") carried by the vector, a novel transformed yeast which is produced by transforming a yeast with said recombinant DNA, and a method for the production of gB HSV proteins in a high yield and with high purity by culturing said transformed yeast in a suitable medium. In developed countries, population having immunity against HSV has recently decreased, and hence, the frequency of serious HSV infections such as herpes genitalis, neonatal herpes infection and herpes encephalitis increased in these countries. In order to prevent such HSV infections, vaccines are useful. There have already been proposed some vaccines such as attenuated vaccines comprising attenuated HSV and inactivated vaccines containing HSV DNA. It is known, however, that HSV includes some problems such as latent infection and carcinogenicity, and that the conventional attenuated vaccines and inactivated vaccines include such side effects and hence are not suitable in practical viewpoint. Cells infected by HSV produce several glycoproteins [e.g. gB, gC, gD, gE, etc., the nomenclature of gA and gB has been standardized as "gB" in International Herpes Virus Workshop (Oxford, England) in 1983]. Since it has been found that these glycoproteins show important functions as an antigen for inhibiting HSV infection, various studies have been done on component vaccines comprising these glycoproteins. For instance, Cappel et al. have reported that glycoproteins extracted from HSV-infected cells or virus particles are effective as an antigen for preventing HSV infections [cf. Cappel et al., Arch. Virol., 73 , 61 (1982)]. However, the component vaccine comprising such glycoproteins extracted from HSV-infected cells or virus particles contains plenty of proteins origined from the host cells and bars the problem of side effects due to the extra proteins. In order to obtain suitable component vaccine having no side effects, it is necessary to obtain highly purified glycoproteins. The present inventors aimed at gB which is one of the glycoproteins and have experimentally confirmed by an experiment in mice that the highly purified gB is very effective [cf. Kino, Cellular Technology, 3 , 120 (1984)]. The glycoprotein gB- is usually produced by inoculating a virus into culture cells and then culturing the cells. However, this method is troublesome in the procedure because of handling infectious material and in the complicated steps, and further, it is impossible to confirm the complete removal of viral DNA carrying carcinogenic gene. Thus, it is very difficult to produce a practically safe component vaccine from the natural glycoprotein gB. The present inventors have intensively studied on a safe vaccine containing no carcinogenic gene by isolating the gB gene and expressing said gene or a fragment thereof in yeast. They have accomplished the isolation of the gB gene and then found that when the isolated gB gene or a fragment thereof is recombined into a specific plasmid vector containing yeast gene and E. coli gene and carrying the expression control region of the repressible acid phosphatase gene of yeast under control of said phosphatase promoter, there is obtained the desired recombinant DNA which is useful for transforming a yeast. When this transformed yeast is cultured under suitable conditions it can produce the desired HSV gB proteins. The present inventors have further found that when a part of the 3'-region (tail) of the gB gene is removed by treating the gB gene with the restriction enzyme Sac I and the resulting DNA fragment containing about 90 % of the total gB gene is inserted into the Sac I site of the above plasmid vector, there is obtained a new recombinant DNA which is useful for transforming a yeast. The obtained transformed yeast can express the HSVgB proteins as a chimeric protein which shows gB activity and is useful for the preparation of herpes simplex virus vaccines. An object of the present invention is to provide a recombinant DNA containing a HSV gB gene according to claim 1 which is suitable for transforming a yeast. Another object of the invention is to provide a yeast transformed with said recombinant DNA. A further object of the invention is to provide a method for the production of HSV gB proteins, preferably chimeric Proteins, using said transformed yeast. These objects and advantages of the present invention will be apparent to persons skilled in the art from the following description. Fig. 1 shows the structure of plasmid pG containing the BamHI-G fragment of HSV DNA. Fig. 2 shows the structure of plasmid pGBX. Fig. 3 shows the base sequence of the HSVgB gene and the upstream region thereof. Fig. 4 shows the structure of plasmid pGAB which is obtained by replacing the Apa I site of plasmid pGBX with an Xho I site. Fig. 5 shows a restriction enzyme map of the region containing the gB gene. Fig. 6 (A) - (E) show the base sequence of/HSVgB gene. Fig. 7 shows the structure of shuttle vector pONY]. Fig. 8 shows the structure of plasmid pAM 82 (sac). Fig. 9 shows the structure of recombinant plasmid pONYGB containing theHSVgB gene of the present invention. Fig. 10 shows the structure of recombinant plasmid pONYGBS wherein a part of the 3'-region of the gB gene is removed. Fig. 11 shows the structure of plasmid pAMGB1 wherein about 10% of the 3'-region of the gB gene is removed. Fig. 12 shows the base sequence of the gB gene - vector recombination site of the plasmid -pAMGB1. The desired recombinant DNA of the present invention can be produced using a specific plasmid vector containing a yeast gene and an E. coli gene and carrying the expression control region of the repressible acid phos phatase gene of yeast and then recombining the HSVgB gene, losing about 10 % of the 3'-region of the gene into said vector under control of the phosphatase promoter. The recombinant DNA thus produced is used for transformation of a yeast. When the transformed yeast is cultured under suitable culture conditions, preferably under the conditions that the acid phosphatase promoter is not repressed, the desired HSV gB proteins and HSV gB chimeric proteins are synthesized. The recombinant DNA, transformed yeast and the production of HSV gB proteins of the present invention are illustrated in more detail below with reference to preferred embodiments thereof. (1) Production of HSVgB gene-containing fragments The HSVgB gene used in the present invention is the HSVgB DNA which is cloned in E. coli . (A) As to the gB gene of HSV (KOS strain: P.S.E.B.M., 1964, Vol. 115) the position on the virus DNA (0.348 - 0.366 map units) and the base sequence have been determined by Bjik et al. [cf. David J. Bjik et al., Virology, 133 , 301 - 314 (1984)]. The HSVgB gene to be inserted into a shuttle vector in the present invention is present in a fragment having about 8 kb (0.345 - 0.399 map units) which is obtained by treating HSV DNA with the restriction enzyme BamHI, said fragment being hereinafter referred to as "BamHI-G fragment". The HSVgB-containing fragment can be prepared by cleaving HSV DNA with BamHI, and cloning the obtained BamHI-G fragment as follows. Virus DNA is isolated from HSV which has been grown on Vero cells, the virus DNA is cleaved with the restriction enzyme BamHI, and then the resulting BamHI-G fragment is isolated and extracted by subjecting the BamHI-cleaved HSV-DNA to agarose gel electrophoresis. The BamHI-G fragment is ligated using T₄ ligase into the E. coli plasmid pBR322 which was previously treated with BamHI. E. coli χ1776 is transformed with the above reaction mixture. Among the transformants thus obtained, a strain having ampicillin resistance (Ap r ) and tetracycline sensitivity is selected. The obtained strain is amplified and plasmid PG containing the BamHI-G fragment is isolated. This plasmid pG has the structure shown in Fig. 1. The plasmid pG thus obtained is cleaved with BamHI and Xho I to give a fragment (3.5 kb) containing the HSVgB gene. The fragment thus obtained is isolated by agarose gel extraction and then is ligated with T₄ ligase into a fragment (2.6 kb) of the E. coli plasmid pACYC177 (Chang, A.C.Y., Cohen, S.N.; J.Bacteriol.134, 1141-1156 (1978)*which was previously treated with BamHI and Xho I. E. coli is transformed with the above reaction mixture, and the resulting transformant having ampicillin resistance is amplified, and then plasmid pGBX containing the HSVgB gene is obtained from * see EP-A-105149 page 17, lines 14-15 the amplified cells. This plasmid pGBX has the structure shown in Fig. 2. According to the dideoxy method [cf. "Proteins, Nucleic acids and Enzymes", Vol. 29, No. 4, 294-306 (1984)], the base sequence of the plasmid pGBX (from the Xho I site to the side of HSV DNA, about 300 bp) is determined (Fig. 3). This sequence corresponds to the base sequence reported by Bjik et al. In the above plasmid pGBX, there is about 250 bp from the Xho I site to the translation initiation codon ATG of the gB gene, and at the upstream of ATG, -14 bp to -19 bp, there is an Apa I site. Accordingly, the plasmid pGBX is partially cleaved with the restriction enzyme Apa I and is converted into flush end by treating with DNA polymerase and then re-cyclized with an Xho I linker to give plasmid pGAB wherein only the Apa I site at -14 bp to -19 bp is converted into/Xho I site. This plasmid pGAB has the structure as shown in Fig. 4. The HSV DNA is amplified by cloning in E. coli , and then, it is usually treated with an appropriate restriction enzyme to give a desired fragment. The fragment thus obtained is used for the subsequent construction of the plasmid as mentioned hereinafter. (B) As to the plasmid pG obtained in the above (A), the base sequence of the Sma I - Sac I region containing gB gene is determined by dideoxy method [cf. "Proteins, Nucleic acids and Enzymes", Vol. 29, No. 4, 294-306 (1984)]. That is, as is shown in the accompanying Fig. 5, the Sma I - Sac I segment is divided into smaller segments by various restriction enzymes, and segements thus obtained (shown by the arrow symbols ← → ) are each inserted into an M 13 vector for determining the base sequence (manufactured by Pharmacia Japan K.K.) and then the resultants are subjected to sequencing. As a result, as is shown in Fig. 6 (A) - (E), there is an open reading frame of 2712 bp (from ATG to TGA) in the Sma I - Sac I region, and 903 amino acids are encoded. When this base sequence is compared with the base sequence reported by Bjik et al., 6 bases are different (as amino acids, two amino acids are different). Based on the base sequence found above, it is understood that basic amino acids are located at the 3'-region of the gB gene. Accordingly, in order to express the gB gene in yeast, it is preferable to design a vector in which a region other than the 3'-region is inserted downstream of the promoter for expression (i.e. acid phosphatase promoter). Thus , the above plasmid pG is treated with the restriction enzyme Sac I to remove the 3'-region of the gene to obtain a fragment (2.7 kb), which is hereinafter referred to as "Sac I fragment" . This fragment contains about 90 % of the gB gene and encodes 816 amino acids. It is used for the construction of a plasmid for expressing HSVgB gene as described hereinafter. (2) Shuttle vector The shuttle vector used in the present invention is a plasmid vector which contains both a yeast, gene and an E. coli gene and carries the repressible acid phosphatase gene of yeast, e.g. Saccharomyces cerevisiae. The terms"yeast gene" and " E. coli gene" in this context in principle refer to DNA sequences which are derived from yeast and from E. coli and its plasmids, respectively. The yeast gene contains a DNA sequence which is necessary for replication of a plasmid in yeast independently from chromosome and contains optionally a gene useful as a selective marker of the transformed yeast. It is found by the present inventors that, as such a DNA sequence for the replication, the combination of ars 1 and 2 µori is quite preferable since the plasmid is provided with an outstanding stability so that the plasmid copy number is very high with the least loss of the plasmid during the transformation and the culturing of the transformed yeast, thereby assuring high production of the desired herpes simplex virus proteins. The selective marker includes, for example, a leucine-producing gene, a histidine-producing gene, a tryptophane-producing gene, a uracil-producing gene, an adenine-producing gene, or the like, which may be used alone or in combination of two or more thereof. The E. coli gene contains a DNA sequence necessary for the replication of the plasmid within cells of E. coli , for example, a DNA sequence of a replication initiating region of plasmid Col EI, and preferably contains a gene useful as a selective marker of the transformed E. coli . The selective marker includes, for example, an ampicillin-resistant gene, a kanamycin-resistant gene, tetracycline-resistant gene, chloramphenicol-resistant gene, or the like, which may be used alone or in combination of two or more thereof. Commonly used E. coli DNA is pBR322 which contains an ampicillin resistant gene and tetracycline-resistant gene. The shuttle vector used in the present invention is characteristic in that it carries the repressible acid phosphatase promoter of the yeast. This acid phosphatase promoter is usually a promoter of a gene encoding a polypeptide of 60,000 dalton (P60) which constitutes the phosphatase. Suitable examples of the shuttle vector are produced from shuttle vector pAT 77 wherein yeast DNA containing ars 1 , 2 µori and a leucine-producing gene (Leu 2) as the yeast gene is combined with E. coli plasmid pBR322, i.e. by treating the shuttle vector pAT 77 with exonuclease BAL 31 to delete a part or whole of the structural gene of acid phosphatase and further optionally various regions upstream therefrom up to -100 bp, preferably from +1 to -50 bp. A representative example is the shuttle vector pAM 82 wherein upstream till -33 bp is deleted. The method for the production of these shuttle vectors is disclosed in Japanese Patent First Publication No. 31799/1984 and EP-A-105149. The shuttle vectors pAT 77 and pAM 82 carried by Saccharomyces cerevisiae (i.e. Saccharomyces cerevisiae AH 22/pAT 77 and Saccharomyces cerevisiae AH 22/pAM 82, respectively) have been deposited at Fermentation Research Institute, Agency of Industrial Science and Technology, Japan under Budapest Treaty as "FERM BP-324" and "FERM BP-313", respectively. The shuttle vector pAM 82 has an Xho I site downstream of the acid phosphatase promoter and also a Pvu II site further downstream therefrom. In order to insert the HSVgB gene (i.e. Xho I - BamHI fragment) into the vector, pAM 82 is cleaved with the restriction enzyme Pvu II, and a BamHI linker is bound to the resulting flush ends, by which the combined fragment is re-cyclized to form a plasmid pONY1 having a structure as shown in Fig. 7. This plasmid pONY₁ can express a foreign gene in the pure form under the control of acid phosphatase promoter, and the site to be recombined can readily be cleaved by treating it with restriction enzymes BamHI and Xho I, and hence, this shuttle vector is, suitable for recombining genes required. Besides, when the above shuttle vector pAM82 is cleaved with Xho I in order to recombine it with the HSVgB gene (Sac I fragment, 2.7 kb) and then is converted into flush end with DNA polymerase, and a Sac I linker is bound to said site, by which the combined fragment is re-cyclized , plasmid pAM 82 (Sac) results which has the structure shown in Fig. 8. This plasmid pAM 82 (Sac) can express a foreign gene in the pure form under the control of acid phosphatase promoter, and the site to be recombined can readily be cleaved by treating it with the restriction enzyme Sac I, and inserting a DNA fragment having Sac I-ends. (3) Construction of recombinant DNA (HSV gene-expression plasmid) (A) The recombinant plasmid of the present invention, i.e. a plasmid recombined with HSV gene, can be prepared by firstly cleaving the above shuttle vector pONY1 with restriction enzymes BamHI and Xho I, linking thereto the above HSVgB gene [i.e. a fragment (3.3 kb) containing the gB gene which is obtained by cleaving the plasmid pGAB with BamHI and Xho I], and amplifying the resulting plasmid in E. coli to obtain the desired recombinant plasmid pONYGB having the structure shown in Fig. 9. (B) In order to express a material having gB antigenicity and immunogenicity more effectively, a plasmid in which the gB gene without its 3'-region is inserted is prepared as follows: The plasmid pONYGB obtained above is cleaved with the restriction enzyme Sac I and is converted into flush ends with DNA polymerase. Thereto the universal translation terminator is ligated : 5'-d[GCTTAATTAATTAAGC]-3' (sold by Amersham Japan K.K.) and then the plasmid DNA is re-cyclized. The thus obtained plasmid pONYGBS has the structure shown in Fig. 10, wherein at the Sac I site in the gB gene, the termination codon (TAA) is inserted, and hence, the translation of the m-DNA is stopped at this site and thus about 90 % of gB gene (consisting of 816 amino acids) is expressed. The plasmid wherein about 10 % of the tail region of the gB gene is removed can express a larger amount of proteins having gB antigencity and immunogenicity in comparison with the plasmid pONYGB. (C) The recombinant plasmid containing the HSV gene without the 3'- region can also be prepared by cleaving the above shuttle vector pAM 82 (Sac) with the restriction enzyme Sac I, linking thereto the above HSVgB gene (Sac I fragment, 2.7 kb), and amplifying the resultant in E. coli to give the desired recombinant plasmid pAMGB1 having the structure shown in Fig. 11. In this plasmid, the gB gene is inserted downstream of the acid phosphatase promoter, and 816 amino acids are encoded in said gB gene, and thereafter further 4 amino acids are encoded utilizing the base sequence at the vector side in the same frame, and then the frame is stopped at TGA. Thus, totally 820 amino acids are encoded (cf. Fig. 12). (4) Transformation of yeast The yeast to be transformed includes a mutant strain of yeast which is complemental with the selective marker gene of the transformed yeast carried on the plasmid, for example, a leucine-requiring mutant, Saccharomyces cerevisiae AH 22 [a, leu 2, his 4, Can 1 (Cir + )]' (cf. Hinnen, A. et al., Proc. Natl. Acad. Sci., U.S.A., 75 , 2157-2161 , 1978) or Saccharomyces cerevisiae AH 22 pho 80 [a, leu 2, his 4, Can 1 (Cir + )] (cf. Thoe, A. et al., J. Bacteriol., 145 , 221-232, 1981). After amplifying by E. coli, the recombinant plasmid is applied to the mutant strain of yeast in a usual manner, for example, by mixing the plasmid DNA with cells obtained by converting into spheroplast, followed by mixing cells treated with calcium and the plasmid DNA, by which the transformation is effected. The desired transformed yeast is selected and isolated from the yeast culture thus treated based on the expression of a gene complemental with the mutation of the host yeast carries on the vector, for example, expression of a leucine-producing gene. In addition to the above-mentioned leucine-requiring strain, various other mutant strains such as a histidine-requiring strain, tryptophane-requiring strain, uracil-requiring strain, adenine-requiring strain, or the like can be used as the yeast. (5) Culture of transformed yeast and production of HSVgB The transformed yeast obtained above is cultured in a medium containing phosphoric acid in a usual manner, the culture cells in logarithmic growth phase are transferred to an inorganic phosphate free medium and then are cultured under a condition that the acid phosphatase promoter is not repressed. After the culture, the produced cells are collected and lysed in a usual manner to give a lysed cell solution containing a large amount of the desired HSVgB [HSV chimeric proteins in case of using the yeast transformed with the plasmid pAM 82 (Sac)]. Depending on the kind of an yeast, for instance, when pho 80 mutant strain is used, the culture is not necessarily required to be carried out under the condition that the acid phosphatase promoter is not repressed, but may be done under a usual condition to give directly the desired HSVgB or HSV chimeric proteins in a large amount. The HSVgB or HSV chimeric proteins can be purified by conventional purification methods. For instance, the proteins-containing solution is passed through a column packed with a gel bound with an anti-gB antibody, and then the adsorbed gB is eluted with 3 M KSCN. The gB thus obtained has the same immunological properties as those of the natural gB obtained from HSV-infected cells and can be used for the preparation of HSV vaccine and diagnostic reagents. The recombinant DNA, transformed yeast, and the production of HSVgB of the present invention are illustrated by the following example, but should not be construed to be limited thereto. Example (1 ) Preparation of DNA containing HSVgB gene: (i) Preparation of HSV-1 DNA: Vero cells (about 5 x 10⁸ cells) is infected with 0.5-1 PFU/cell of HSV type 1 (HSV-1 ) KOS strain and the cells are culured at 37°C for 20-24 hours. When the cells are sufficiently modified, the culture mixture is centrifuged at 28,000 r.p.m. for 1 hour to separate the infected cells and the supernatant, and thereby pellets of infected cells (2-3 ml) are isolated. The pellets are suspended in a phosphate buffered saline solution (hereinafter, referred to as "PBS") (pH 7.2, 6 ml). The suspension is subjected to ultrasonic treatment (9 KHz, 200 W, for 5 minutes) or to freezing - thawing [repeating three times freezing at -50°C (with acetone-dry ice) and thawing at 37°C] to fracture the cells, and the cell residue is removed by centrifugation at low speed (3,000 r.p.m., 20 minutes). The solution thus obtained is layered on glycerol cusion (5 %, 40 %) and then centrifuged at 35,000 r.p.m. for one hour. The pellets (0.5-1 ml) thus obtained are suspended in PBS (1-2 ml) and are treated with DNase (10 µg/ml) and RNase (0.3 mg/ml) at 37°C for one hour, and to the reaction mixture is added 1/5 volume of 5 x STEP [a mixture of 0.5 % SDS (sodium dodecyl-sulfate), 50 mM Tris-HCl (pH 7.5), 0.4 M EDTA, and 0.1 % proteinase K], and the mixture is reacted at 50°C for 30 minutes. The resulting solution is extracted with an equi-volume of phenol, phenol-chloroform (1 : 1) and chloroform in this order to give an aqueous layer containing DNA. The aqueous layer is dialyzed against TE buffer (20 mM Tris-HCl, 1 mM EDTA, pH 7.5), and thereto is added cold ethanol to precipitate the DNA. The DNA is separated by filtration, dried in vacuum, and then dissolved in an aqueous cesium chloride [Rf 1.3885, incorporated with ethidium bromide (0.04 %) and lauroyl sarcosinate (0.4 %), 5 ml]. The mixture is centrifuged at 4,000 r.p.m. for 72 hours to form a band of HSV-1 DNA. The band is recovered and is washed with isopropyl alcohol to remove ethidium bromide, and then dialyzed against TE buffer. Cold ethanol is added thereto to precipitate HSV-1 DNA. (ii) Cloning of BamHI-cleaved G fragment of HSV-1 DNA: The HSV-1 DNA obtained above (about 100 µg) is treated with a restriction enzyme BamHI in a mixture (0.75 ml) of 73 mM Tris-HCl (pH 8.0), 7 mM MgCl₂, 100 mM NaCl and 2 mM 2-mercaptoethanol at 37°C for 6 hours, and then each fragment is separated by 0.7 % agarose electrophoresis to cut out a gel corresponding to G fragment (0.345-0.399 map units), from which the G fragment is electrophoretically recovered. E. coli pBR322 plasmid (1/10 mole) obtained by cleavage with a restriction enzyme BamHI is reacted with the above G fragment (about 2 µg) in a mixture of 50 mM Tris-HCl (pH 7.9), 10 mM MgCl₂, 20 mM dithiothreitol and 1 mM ATP by using T₄ DNA ligase at 16°C for about 16 hours. The above reaction mixture is added to a liquid of E. coli (0.1 ml) which is prepared by treating a culture broth of E. coli χ1776 (cf. Curtiss, R. III, "Molecular Cloning of Recombinant DNA" ed. Scott, W. A. and Werner, R., page 99, Academic Press, 1977) by the procedure as described in Norgard, M. V., Gene, 3 , 279 (1978), and the mixture is mixed well and allowed to stand at 0°C for 45 minutes. The mixture is applied onto an agar plate containing ampicillin (100 µg/ml) and then incubated at 37°C overnight. The resulting colonies are applied onto both an agar plate containing ampicillin (100 µg/ml) and an agar plate containing tetracycline (100 µg/ml), and are incubated likewise. The colonies which grow only on the agar plate containing ampicillin are selected. pBR322 has an ampicillin-resistant gene and a tetracycline-resistant gene, but when it is inserted with HSV-1 DNA fragment at the BamHI site of the tetracycline-resistant gene, it loses the tetracycline-resistance. Accordingly, the selected colonies contain a recombinant DNA of BamHI-G fragment of pBR322-HSV DNA. From the colonies thus selected, a plasmid is prepared by the procedure as described by K. Matsubara (J. Virol., 16 , 479, 1975). The plasmid thus prepared is subjected to cleavage pattern analysis by treating with various restriction enzymes (e.g. BamHI, Bst EII, Kpn I, Sal I, Sst I, Xho I) to obtain a recombinant DNA of pBR322-BamHI-G fragment wherein BamHI-G fragment of HSV-1 DNA is inserted into pBR322 (hereinafter, referred to as "plasmid pG"). (iii) Base sequence of HSVgB gene: The base sequence of the above plasmid pG containing HSVgB gene is determined as follows: The plasmid pG (10 µl) is dissolved in a mixture (100 µl) of restriction enzymes Sma I and Sac I, and are reacted with Sma I (10 units) and Sac I (10 units) to give a fragment of Sma I - Sac I region containing the gB gene. This Sma I - Sac I fragment is treated with various restriction enzymes such as Sac I, Sac II, Sma I, Pst I, Sal I, Pvu II, Sau 3A and Nar I to obtain smaller fragments as shown in the accompanying Fig. 5 (by the symbols: ← → ), and these smaller segments are each inserted into a cloning vector M 13 mp 11 (sold by Pharmacia Japan) at the Sal I site thereof. According to dideoxy method [cf. "Proteins, Nucleic acids and Enzymes", Vol. 29, No. 4, 284-306 (1984), Item: "Method for the Determination of Base Sequence of DNA by Dideoxy Method"], the base sequence of the smaller fragments is determined. As a result, the Sma I - Sac I region has a base sequence and amino acid sequence of gB protein encoded thereby as shown in the accompanying Fig. 6. Thus, it is clear that the gB gene is composed of 903 amino acids. (iv) Preparation of plasmid pGBX: The plasmid pG (10 µg) obtained in the above (ii) is added to a mixture (100 µl) of 6 mM Tris-HCl (pH 7.5), 6 mM MgCl₂, 6 mM 2-mercaptoethanol and 150 mM NaCl, and thereto are added restriction enzymes BamHI (10 units) and Xho I (10 unites), and the mixture is reacted at 37°C for 2 hours. 3.5 kb fragment DNA is isolated from the reaction mixture by 1 % agarose gel electrophoresis in accordance with the method disclosed by Yasusuke Takagi, "Manual for Procedure of Genetic Engineering", pages 33-34. The thus obtained 3.5 kb fragment DNA (100 ng) is reacted with E. coli plasmid pACYC 177 (which is cleaved with BamHI and Xho I) (10 ng) in a mixture (10 µl) of T₄ ligase (0.1 unit), 6.6 mM MgCl₂ and 10 mM dithiothreitol at 16°C for 8 hours. By using the above reaction mixture, E. coli χ1776 is transformed in the same manner as described hereinbefore, and ampicillin resistant cells are selected from the resulting transformants. From the cells thus selected, a plasmid pGBX containing gB gene is prepared by the procedure as described by K. Matsubara (J. Virol., 16 , 479, 1975). (v) Base sequence of Xho I - Sal I region (1.2 kb) of the plasmid pGBX: The above-obtained plasmid pGBX (10 µg) is dissolved in a mixture (100 µl) of 6 mM Tris-HCl (pH 7.9), 6 mM MgCl₂ and 6 mM 2-mercaptoethanol, and thereto are added restriction enzymes Sal I (10 units) and Xho I (10 units), and the mixture is reacted at 37°C for 2 hours. The reaction mixture is subjected to 1 % agarose gel electrophoresis as above to isolate 1 .2 kb fragment. The thus obtained 1 .2 kb fragment is inserted into a cloning vector M 13 mp 11 (sold by Pharmacia Japan) at the Sal I site thereof, and the base sequence thereof is determined by dideoxy method [cf. "Proteins, Nucleic acids and Enzymes", Vol. 29, No. 4, 294-305 (1984), Item: "Method for the Determination of Base Sequence of DNA by Dideoxy Method"]. As a result, it shows the base sequence as is shown in the accompanying Fig. 3. As is clear from the figure, the Xho I site is distant about 250 bp from the translation initiation codon ATG of the gB gene and further Apa I site is present at 14 bp - 19 bp upstream from the ATG. (vi) Preparation of plasmid pGAB: The above plasmid pGBX is treated in the following manner in order to convert only the Apa I site upstream of the translation initiation codon ATG of the gB gene into Xho I site. Plasmid pGBX (2 µg), Apa I (0.1 unit) and a mixture (50 µl) of 6 mh Tris-HCl (pH 7.5), 6 mM NaCl, 6 mM MgCl₂ and 6 mM 2-mercaptoethanol are mixed and the mixture is reacted at 37°C for 5 minutes. The reaction mixture is subjected to phenol extraction and ethanol precipitation. The resulting DNA is treated with T₄ DNA polymerase (0.1 unit) in a solution (50 µl) of 67 mM Tris-HCl (pH 8.6), 6.7 mM MgCl₂, 10 mM 2-mercaptoethanol, 16.7 mM (NH₄)₂SO₄ which contains 200 µM αATP, αCTP, αGTP and αTTP at 37°C for 30 minutes. The reaction mixture is subjected to phenol extraction and ethanol precipitation. The resulting DNA (1 pmole) is subjected to linking reaction with Xho I linker by using T₄ ligase (0.1 unit) in a mixture (10 µl) of 66 mM Tris-HCl (pH 7.6), 6.6 mM MgCl₂, 10 mM dithiothreitol, 66 µM ATP and Xho I linker (1 pmole) at 16°C for 8 hours. E. coli χ1776 is transformed with the reaction mixture obtained above in the same manner as described hereinbefore. A plenty of clones which grow on an ampicillin-containing plate are selected, and the plasmids are prepared from the selected cells in the same manner as described above. The plasmids are each treated with a restriction enzyme Xho I, and thereby there is selected the desired plasmid pGAB by the patterns in electrophoresis. In the plasmid pGAB, only Apa I site upstream of the translation initiation codon ATG of the gB gene is converted into Xho I site. (vii) Preparation of Sac I fragment wherein the tail region of the gB gene is removed: The plasmid pG (10 µg) obtained in the above (ii) is treated with Sac I (10 units) in a mixture (100 µl) of 6 mM Tris-HCl (pH 7.5), 6 mM MgCl₂, 6 mM 2-mercaptoethanol and 150 mM NaCl at 37°C for 2 hours. The reaction mixture is subjected to 1 % agarose gel electrophoresis and the desired DNA fragment (Sac I fragment) (2.7 kb, containing about 93 % of the gB gene) is extracted and isolated in the same manner as described hereinbefore. (2) Preparation of shuttle vectors: (A) shuttle vector pONY1: Shuttle vector pAM 82 as prepared in the same manner as described in Japanese Patent First Publication No. 31799/1984 is treated as follows in order to convert the Puv II site into BamHI site. A fragment (2 µg) prepared by cleaving the plasmid pAM 82 with Xho I is reacted with T₄ DNA polymerase (0.1 unit) in a mixture (50 µl) of 67 mM Tris-HCl (pH 8.6), 6.7 mM MgCl₂, 10 mM 2-mercaptoethanol, 6.7 µM EDTA and 16.7 mM (NH₄)₂SO₄ which contains 200 µM αATP, αCTP, αGTP and αTTP at 37°C for 30 minutes. The reaction mixture is subjected to phenol extraction and ethanol precipitation. The resulting DNA is reacted with BamHI linker in a molar ratio of 1 : 10 by using T₄ ligase at 16°C for 8 hours, and E. coli χ1776 is transformed with the reaction mixture obtained above in the same manner as described hereinbefore. The ampicillin-resistant cells thus obtained are incubated, and from the cells thus obtained, there is isolated a plasmid pONY1 in the same manner as described hereinbefore. In said plasmid pONY1, the Pvu II site of pAM 82 is converted into BamHI site. (B) Shuttle vector pAM 82 (Sac): Shuttle vector pAM 82 as prepared in the same manner as described in Japanese Patent First Publication No. 31799/1984 is treated as follows in order to convert the Xho I site into Sac I site. A fragment (2 µg) prepared by cleaving the plasmid pAM 82 with Xho I is reacted with T₄ DNA polymerase (0.1 unit) in a mixture (50 µl) of 67 mM Tris-HCl (pH 8.6), 6.7 mM MgCl₂, 10 mM 2-mercaptoethanol, 6.7 µM EDTA and 16.7 mM (NH₄)₂SO₄ which contains 200 µM αATP, αCTP, αGTP and αTTP at 37°C for 30 minutes. The reaction mixture is subjected to phenol extraction and ethanol precipitation. The resulting DNA is reacted with Sac I linker in a molar ratio of 1 : 10 by using T₄ ligase at 16°C for 8 hours, and E. coli χ 1776 is transformed with the reaction mixture obtained above in the same manner as described hereinbefore. The ampicillin-resistant cells thus obtained are incubated, and from the cells thus obtained, there is isolated a plasmid pAM 82 (Sac) in the same manner as described hereinbefore. In said plasmid pAM 82 (Sac), Xho I site of pAM 82 is converted into Sac I site. (3) Preparation of HSVgB expression plasmid: (A) The plasmid pGAB (10 µg) containing whole of HSVgB gene as prepared in the above (1), (iv) is reacted with BamHI (10 units) and Xho I (10 units) in a mixture (100 µl) of 6 mM TrIs-HCl (pH 7.5), 6 mM MgCl₂, 6 mM 2-mercaptoethanol and 150 mM NaCl at 37°C for 2 hours. From the reaction mixture there is isolated a DNA fragment (3.3 kb) containing HSVgB gene by 1 % agarose electrophoresis. Separately, the shuttle vector pONY1 (10 µg) obtained in the above (2), (A) is treated with restriction enzymes BamHI and Xho I in the same manner as described hereinbefore, and from the reaction mixture there is isolated a DNA fragment (10 kb) containing acid phosphatase promoter by 1 % agarose electrophoresis. The 3.3 kb fragement (10 ng) and the 10 kb fragment (10 ng) obtained above are reacted with T₄ ligase (0.1 unit) in a mixture (10 µl) of 66 mM Tris-HCl (pH 7.6), 6.6 mM MgCl₂, 10 mM dithiothreitol and 66 µM ATP at 16°C for 8 hours. E. coli χ1776 is transformed with the reaction mixture obtained above in the same manner as described hereinbefore. The ampicillin-resistant cells thus obtained are incubated, and from the cells thus obtained, there is isolated a recombinant plasmid pONYGB wherein HSVgB gene is inserted at the downstream of the acid phosphatase promoter in the same manner as described hereinbefore. (B) The plasmid pAM 82 (Sac) (1 µg) as prepared in the above (2), (B) is reacted with Sac I (10 units) in a mixture (100 µl) of 6 mM Tris-HCl (pH 7.5), 6 mM MgCl₂, 6 mM 2-mercaptoethanol and 150 mM NaCl at 37°C for 2 hours. The reaction mixture is subjected to phenol extraction and ethanol precipitation, and therefrom there is isolated a DNA fragment (3.3 kb) containing HSVgB gene in the same manner as described above. The fragment (10 ng) obtained above and the 2.7 kb Sac I fragment (100 ng) obtained in the above (1 ) , (vii) are reacted with T₄ ligase (0.1 unit) in a mixture (10 µl) of 66 mM Tris-HCl (pH 7.6), 6.6 mM MgCl₂, 10 mM dithiothreitol and 66 µM ATP at 16°C for 8 hours. E. coli χ1776 is transformed with the reaction mixture obtained above in the same manner as described hereinbefore. The ampicillin-resistant cells thus obtained are incubated, and from the cells thus obtained, there is isolated a recombinant plasmid pAMGB1 in the same manner as described above. In said recombinant plasmid pAMGB1, HSVgB gene losing the tail region (i.e. HSVgB gene having about 90 % of the whole gB gene, 816 amino acids) is inserted at the downstream of the acid phosphatase promoter and at the downstream therefrom a vector-origin gene (four amino acids) is inserted. (4) Transformation of yeast: (A) The starting yeast is Saccharomyces cerevisiae AH 22 [a, leu 2, his 4, can 1 (Cir + )], which has been deposited at Fermentation Research Institute, Agency of Industrial Science and Technology, Japan under Budapest Treaty as "FERM BP-312". The starting yeast is inoculated in YPD medium (100 ml) consisting of 2 % polypeptone, 1 % yeast extract and 2 % glucose, and the mixture is incubated at 30°C overnight, and thereafter, the cells are collected by centrifugation. The cells thus collected are washed with sterilized water (20 ml), suspended in a solution (5 ml) of 1 .2 M sorbitol and Zymolyase-60,000 (manufactured by Seikagaku Kogyo K.K., Japan, 100 µg/ml), and the suspension is allowed to stand at 30°C for 30 minutes to give spheroplast. The spheroplast thus prepared is washed with 1.2 M sorbitol solution three times, and then suspended in a solution (0.6 ml) of 2 M sorbitol, 10 mM CaCl₂ and 10 mM Tris-HCl (pH 7.5). The suspension thus prepared is divided into a small test tube in a volume of 60 µl. To the suspension is added the solution of the recombinant plasmid pONYGB (10 µg) as prepared in the above (3), (A). After mixing well, 0.1 M CaCl₂ (3 µl) is added thereto in a final concentration of 10 mM CaCl₂, and the mixture is allowed to stand at room temperature for 5 to 10 minutes. To the resulting mixture is added each 1 ml of a solution of 20 % polyethylene glycol 4,000, 10 mM CaCl₂ and 10 mM Tris-HCl (pH 7.5), and the mixture is allowed to stand at room temperature for about 20 minutes. The resulting mixture (each 0.2 ml) is added to a medium (10 ml) consisting of 22 % sorbitol, 2 % glucose, 0.7 % yeast nitrogen base amino acid, 2 % YPD, 20 µg/ml histidine and 3 % agar, which is kept at a constant temperature of 45°C. After gently mixing, the mixture is added in a layer onto a plate of minimal medium containing 1.2 M sorbitol which is previously prepared and consists of 0.7 % yeast nitrogen base amino acid, 2 % glucose, 20 µg/ml histidine and 2 % agar and is set thereon. The plate is incubated at 30°C to give a colonie of a leucine-non-requiring yeast. The colonie is incubated in a BurkHorlder minimal medium supplemented with histidine (20 µg/ml) [cf. Tohe, A. et al; J. Bacterol., 113 , 727-738, 1973] to give the desired transformed yeast: Saccharomyces cerevisiae YGB. (B) By using Saccharomyces cerevisiae AH 22 [a, leu 2, his 4, can 1 (Cir + )] (FERM BP-312) as the starting yeast, it is inoculated in YPD medium (100 ml) consisting of 2 % polypeptone, 1 % yeast extract and 2 % glucose, and the mixture is incubated at 30°C overnight, and thereafter, the cells are collected by centrifugation. The cells thus collected are washed with sterilized water (20 ml), suspended in a solution (5 ml) of 1 .2 M sorbitol and Zymolyase-60,000 (manufactured by Seikagaku Kogyo K.K., Japan, 100 µg/ml), and the suspension is allowed to stand at 30°C for 30 minutes to give spheroplast. The spheroplast thus prepared is washed with 1 .2 M sorbitol solution three times, and then suspended in a solution (0.6 ml) of 2 M sorbitol, 10 mM CaCl₂ and 10 mM Tris-HCl (pH 7.5). The suspension thus prepared is divided into a small test tube in a volume of 60 µl. To the suspension is added the solution of the recombinant plasmid pAMGB1 (10 µg) as prepared in the above (3), (B). After mixing well, 0.1 M CaCl₂ (3 µl) is added thereto in a final concentration of 10 mM CaCl₂, and the mixture is allowed to stand at room temperature for 5 to 10 minutes. To the resulting mixture is added each 1 ml of a solution of 20 % polyethylene glycol 4,000, 10 mM CaCl₂ and 10 mM Tris-HCl (pH 7.5), and the mixture is allowed to stand at room temperature for about 20 minutes. The resulting mixture (each 0.2 ml) is added to a medium (10 ml) consisting of 22 % sorbitol, 2 % glucose, 0.7 % yeast nitrogen base amino acid, 2 % YPD, 20 µg/ml histidine and 3 % agar, which is kept at a constant temperature of 45°C. After gently mixing, the mixture is added in a layer onto a plate of minimal medium containing 1.2 M sorbitol which is previously prepared and consists of 0.7% yeast nitrogen base amino acid, 2 % glucose, 20 µg/ml histidine and 2 % agar and is set thereon. The plate is incubated at 30°C to give a colonie of a leucine-non-requiring yeast. The colonie is incubated in a BurkHorlder minimal medium supplemented with histidine (20 µg/ml) [cf. Tohe, A. et al; J. Bacterol., 113 , 727-738, 1973] to give the desired transformed yeast. (5) Production of HSVgB by the transformed yeast: (A) The colonie of the transformed yeast obtained in the above (4), (A) is applied onto an agar plate of BurkHolder minimal medium supplemented with histidine (20 µg/ml) and incubated at 30°C to form a colonie (in order to confirm the transformant requiring no leucine). The resulting cells are separated from the colonie, inoculated in BurkHolder minimal medium (10 ml) supplemented with histidine (20 µg/ml) and incubated at 30°C. After about 24 hours, the cells in logarithmic growth phase are collected by centrifugation and are suspended in a minimal medium (10 ml) containing no phosphoric acid (which is prepared by replacing KH₂PO₄ in BurkHolder minimal medium with KCl, followed by supplementing 20 µg/ml histidine) in a cell concentration of about 4 x 10⁶ cells/ml. After incubating at 30°C for about 24 hours, the culture broth is centrifuged at 4,000 r.p.m. for 10 minutes to cellect the cells. The cells thus separated are suspended in a solution (3 ml) of 1.2 M sorbitol, 50 mM phosphate buffer (pH 7.2), 14 mM 2-mercaptoethanol and 100 µg/ml Zymolyase-60,000 (manufactured by Seikagaku Kogyo K.K., Japan), and the mixture is gently shaken at 30°C for 30 minutes to give spheroplast. The spheroplast is collected by centrifugation and is well suspended in 50 mM phosphate buffer (pH 7.2, 1 ml) containing 1 % Tritone χ-100, and the mixture is vigorously stirred with glass beads to fracture the cells. The resulting fractured mixture is centrifuged at 5,000 r.p.m. for 10 minutes, and the resulting supernatant is taken as the yeast-lysed solution. As to the supernatant, the gB antigen activity was measured by an enzyme immunoassay. The results are shown in Table 1. Besides, the fractured solution obtained above (each 1 ml) was subcutaneously administered to guinea pigs (5 animals) four times in each other week. As a result, there was observed neutralizing antibody in all guinea pigs. (B) In the same manner as described in the above (A) except that the colonie of transformed yeast obtained in the above (4), (B) is used instead of the colonie of transformed yeast obtained in (4), (A), the cells of the transformed yeast are collected, fractured and centrifuged likewise. As to the supernatant, the gB antigen activity was measured by an enzyme immunoassay, likewise. The results are shown in Table 2. Besides, the fractured solution obtained above (each 1 ml) was subcutaneously administered to guinea pigs (5 animals) four times in each other week. As a result, there was observed neutralizing antibody in all guinea pigs.

Claims: A recombinant plasmid which comprises a plasmid vector containing (a) a yeast DNA sequence; (b) an Escherichia coli DNA sequence; (c) the expression control region of the repressible yeast acid phosphatase gene; and (d) recombined to and under the control of (c) a DNA fragment in which part of the 3' region is removed and the resulting DNA fragment comprises about 90% of the whole herpes simplex virus (HSV) gB gene encoding 903 amino acids. The recombinant plasmid according to claim 1, wherein said expression control region (c) is derived from a gene of a polypeptide of 60,000 dalton (P60) which constitutes the phosphatase, a part or whole of the structural gene of the phosphatase, wherein a region upstream therefrom in the range of from +1 (ATG) to -100 bp is optionally deleted. The recombinant plasmid according to claim 1 or 2, wherein the yeast DNA sequence (a) contains ars 1, the 2µ ori and a selective marker gene for a transformed yeast which is a leucine-producing gene, a histidine-producing gene, a tryptophane-producing gene, a uracil-producing gene, or an adenine-producing gene, or a combination of two or more thereof. The recombinant plasmid according to any one of claims 1 to 3, wherein the E. coli DNA sequence (b) contains a DNA sequence which is necessary for replication of the plasmid in cells of E. coli and a selective marker gene for a transformed E. coli which is an ampicillin-resistance gene, a kanamycin-resistance gene, a tetracycline-resistance gene, or a chloramphenicol-resistance gene, or a combination of two or more thereof. The recombinant plasmid according to claim 4, wherein the E. coli DNA sequence (b) is the E. coli plasmid pBR322 that contains an ampicillin-resistance gene and a tetracycline-resistance gene. The recombinant plasmid according to any one of claims 1 to 5, wherein the DNA fragment (d) does not contain the 3'-region of the gB gene. The recombinant plasmid according to any one of claims 1 to 6, wherein the DNA fragment (d) without the 3'-region of the gB gene is an Apa I/Sac I fragment of the HSV gB gene. The recombinant plasmid according to any one of claims 1 to 6, wherein the DNA fragment (d) without the 3'-region of the gB gene is a fragment containing about 90% of the gB gene which is obtainable by treating the gB gene with the restriction enzyme Sac I. A transformed yeast which is prepared by transforming a yeast with the recombinant plasmid according to any one of claims 1 to 8. The transformed yeast according to claim 9, wherein the starting yeast is the leucine-requiring mutant strain Saccharomyces cerevisiae AH 22 [a, leu 2, his 4, Can 1 (Cir + )] or Saccharomyces cerevisiae AH 22 pho 80. A method for the production of the herpes simplex virus gB protein, which comprises culturing the transformed yeast of claim 9 or 10 in order to produce the herpes simplex virus gB protein and collecting the protein. The method according to claim 11 , wherein the culturing of the transformed yeast is carried out under conditions where the acid phosphatase promoter is not repressed. A method for the production of a recombinant plasmid according to any one of claims 1 to 8 , which comprises inserting the herpes simplex virus gB gene into a shuttle vector downstream of the expression control region (c) and under the control of the phosphatase promoter contained in (c). A method for the production of a transformed yeast, which comprises constructing a recombinant plasmid according to any one of claims 1 to 8 by inserting the herpes simplex virus gB gene into a shuttle vector down-stream of the expression control region (c) and under the control of the phosphatase promoter contained in (c) and transforming a yeast with the resulting recombinant plasmid according to any one of claims 1 to 8 .

Inventors: ETO, TATSUO, KINO, YOICHIRO, MAKIZUMI, KEIICHI, NOZAKI, CHIKATERU, OHTOMO, NOBUYA
Applicants: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Application year: 1985
Main classification: C12N15
IPC codes: A61K39, C12N15, C07K14